Period prevalence and cumulative incidence of lamivudine resistance and its associated factor in chronic hepatitis B patient in Hospital Universiti Sains Malaysia (HUSM)

Background: Lamivudine is an established treatment options for chronic hepatitis B (CHB), however development of viral resistance followed by virological breakthrough made it a less favourable as a first line treatment option. While the alternatives such as entecavir and tenofovir are favoured for...

Description complète

Détails bibliographiques
Auteur principal: Ismail, Mohd Sharizan
Format: Thèse
Langue:anglais
Publié: 2018
Sujets:
Accès en ligne:http://eprints.usm.my/46573/
Abstract Abstract here

Documents similaires